• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Gastroenterological Surgery >Application of liquid biopsy for surgical management of pancreatic cancer
【24h】

Application of liquid biopsy for surgical management of pancreatic cancer

机译：液体活检在胰腺癌外科治疗中的应用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Although drug development over the past decade has gradually improved the prognosis of PDAC, the prognosis remains extremely poor. The predominant determinant of a poor prognosis is that patients are already at the advanced stage when they are diagnosed. Therefore, it is essential to detect early‐stage PDAC to ensure a good prognosis. However, in general, being asymptomatic at the early stage makes the detection of early‐stage PDAC very difficult. Recently, much attention has been focused on the utility of a liquid biopsy as a biomarker. Theoretically, early‐stage tumors can be detected even under asymptomatic conditions. A number of studies on liquid biopsies have been reported so far. Several biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCS), and exosomes, are used in liquid biopsies, with the potential to be applied to the clinical setting. Each biomarker is reported to have different utilities, such as the detection of early‐stage disease, the differential diagnosis of PDAC from other types of pancreatic tumors, the prediction of the prognosis or risk of recurrence, and monitoring the treatment response. In this review, we focus on ctDNA, CTCS, and exosomes as representative liquid biopsy biomarkers and describe the specific functions of each biomarker in the treatment of PDAC. Furthermore, we discuss the application of liquid biopsies, especially for the surgical management of PDAC.
机译：胰腺导管腺癌（PDAC）是最致命的癌症形式之一。虽然过去十年的药物发展逐渐改善了PDAC的预后，但预后仍然非常差。预后差的主要决定蛋白是患者已经在诊断出患者处于晚期阶段。因此，对于检测早期PDAC至关重要以确保良好的预后。然而，一般而言，早期阶段的无症状使得检测早期的PDAC非常困难。最近，很多关注都集中在液体活检作为生物标志物的效用。理论上，即使在无症状条件下也可以检测早期肿瘤。迄今为止已经报道了许多关于液体活检的研究。几种生物标志物，包括循环肿瘤DNA（CTDNA），循环肿瘤细胞（CTC）和外泌体，用于液体活组织检查，潜力将应用于临床环境。据报道，每种生物标志物都有不同的公用事业，例如检测早期疾病，PDAC的差异诊断来自其他类型的胰腺肿瘤，预测预后或复发的风险，并监测治疗反应。在本次综述中，我们专注于CTDNA，CTC和外来体作为代表性的液体活组织检查生物标志物，并描述了每种生物标志物治疗PDAC的特定功能。此外，我们讨论液体活检的应用，特别是对于PDAC的手术管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号